HighTower Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

HighTower Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-100	Closed	-$3.55K	–	3997
2024 Q2	$3.55K	Buy	+100	New	+$43.4K	﹤0.01%	3501
2023 Q2	–	Sell	-100	Closed	-$1.02K	–	3717
2023 Q1	$1.02K	Buy	+100	New	+$30K	﹤0.01%	3312
2020 Q3	–	Sell	-700	Closed	-$3K	–	2710
2020 Q2	$3K	Buy	+700	New	+$190K	﹤0.01%	2369

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

HighTower Advisors's VRTX Position: Q1 2026 in Review

HighTower Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 38% in Q1 2026, buying an estimated $8.45M and bringing the position to 65,684 shares worth $29.3M. The position accounts for 0.03% of the portfolio, ranked #498.

HighTower Advisors first reported a position in VRTX in Q2 2013 and has held it in 51 quarters since. The position peaked at $33.4M in Q4 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

HighTower Advisors held 65,684 shares of Vertex Pharmaceuticals worth $29.3M as of Q1 2026.
HighTower Advisors bought 18,125 Vertex Pharmaceuticals shares in Q1 2026, an estimated $8.45M.
Vertex Pharmaceuticals made up 0.03% of HighTower Advisors's portfolio in Q1 2026, its #498 holding.
HighTower Advisors first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
HighTower Advisors's Vertex Pharmaceuticals position peaked at $33.4M in Q4 2023.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.